OUTLOOK THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
OUTLOOK THERAPEUTICS, INC. (OTLK) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 0.90% for the 12-month period ending 2025-09-30, per its 10-K filed 2025-12-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2025-12-19
- OUTLOOK THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was 0.90%.
- OUTLOOK THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -2.50%, a 457.14% decline from fiscal 2023.
- OUTLOOK THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was 0.70%.
- OUTLOOK THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was 0.40%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|
| 2025-09-30 | 0.90% 10-K · filed 2025-12-19 | |
| 2024-09-30 | -2.50% 10-K · filed 2025-12-19 | |
| 2023-09-30 | 0.70% 10-K · filed 2024-12-27 | -0.70% 10-K · filed 2023-12-22 |
| 2021-09-30 | 0.40% 10-K · filed 2022-12-29 | |
| 2020-09-30 | -0.30% 10-K · filed 2021-12-23 | |
| 2019-09-30 | -0.20% 10-K · filed 2020-12-23 | |
| 2018-09-30 | -0.60% 10-K · filed 2019-12-19 | |
| 2017-09-30 | -2.80% 10-K · filed 2018-12-18 | |
| 2016-09-30 | 0.00% 10-K · filed 2017-12-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |